Inflammaging: The Chronic Low-Grade Inflammation That Accelerates Aging (And How to Reverse It)

What Is Inflammaging?

Inflammaging is a portmanteau coined by immunologist Claudio Franceschi in 2000 to describe the chronic, low-grade, sterile pro-inflammatory state that accumulates with advancing age. Unlike acute inflammation — the rapid, targeted immune response to infection or injury that resolves within days — inflammaging is persistent, systemic, and operates below the threshold of clinical symptoms. It is not fighting a pathogen. It is the aging immune system misfiring chronically in the absence of a threat.

The phenomenon is paradoxical: the same inflammatory pathways that evolved to protect us from infection become, over decades of chronic activation, primary drivers of the diseases most likely to kill us. Franceschi and Campisi's 2014 review in Journal of Gerontology synthesized the evidence across species and population cohorts, establishing inflammaging as a central hallmark of aging biology — now recognized alongside genomic instability, telomere attrition, epigenetic alterations, and mitochondrial dysfunction.

The Biomarkers: How to Measure Inflammaging

Inflammaging has measurable molecular signatures in blood. These are not exotic research tools — most are available through standard or slightly extended clinical panels:

Interleukin-6 (IL-6)

IL-6 is the most consistent biomarker of inflammaging across population studies. It is a pleiotropic cytokine produced by immune cells, adipose tissue, skeletal muscle (acutely during exercise), and — critically in aging — by senescent cells. Serum IL-6 rises progressively with age and is independently associated with frailty, sarcopenia, cognitive decline, cardiovascular disease, and all-cause mortality in cohort studies including the InCHIANTI study (Ferrucci et al. 2002). Baseline IL-6 below 1–2 pg/mL is generally considered within range; values trending upward over time carry prognostic significance.

High-Sensitivity C-Reactive Protein (hs-CRP)

CRP is synthesized by the liver in response to IL-6 signaling, making it a downstream but practical proxy for systemic inflammation. The landmark JUPITER trial (Ridker 2008) demonstrated that individuals with LDL below 130 mg/dL but hs-CRP above 2 mg/L had cardiovascular event rates similar to those with elevated LDL — establishing hs-CRP as an independent cardiovascular risk factor. The American Heart Association's risk stratification: hs-CRP below 1.0 mg/L = low cardiovascular risk; 1.0–3.0 mg/L = average risk; above 3.0 mg/L = high risk. From a longevity standpoint, the target is below 1 mg/L. hs-CRP above 10 mg/L suggests acute infection or injury and should be retested.

TNF-α (Tumor Necrosis Factor-alpha)

TNF-α is a master pro-inflammatory cytokine produced by macrophages and senescent cells. Chronically elevated TNF-α drives insulin resistance (by interfering with insulin receptor signaling), muscle wasting (by activating the ubiquitin-proteasome pathway in skeletal muscle), and neuroinflammation. In the context of inflammaging, serum TNF-α above 8–10 pg/mL is associated with accelerated sarcopenia and cognitive decline in aging cohorts.

IL-1β (Interleukin-1 beta)

IL-1β is a potent pro-inflammatory cytokine primarily released by the NLRP3 inflammasome — a molecular sensor that detects cellular damage signals including oxidized lipids, uric acid crystals, and mitochondrial DNA. In aging, the NLRP3 inflammasome becomes constitutively more activated, contributing to the chronic IL-1β release seen in inflammaging. IL-1β plays a central role in atherosclerosis (Ridker's CANTOS trial showed that targeting IL-1β with canakinumab reduced major cardiovascular events in humans), neuroinflammation, and gout.

The centenarian observation is among the most compelling in aging biology: multiple studies of individuals aged 100 or older consistently show IL-6, CRP, and TNF-α levels significantly below those of average 70-year-olds — suggesting that keeping inflammation suppressed over decades is a defining feature of extreme longevity, not an incidental correlation.

The Five Drivers of Inflammaging

1. Senescent Cell SASP

Cellular senescence — the state in which cells permanently exit the cell cycle after DNA damage, replicative exhaustion, or oncogenic stress — is a normal tumor-suppressor mechanism. The problem: senescent cells secrete a cocktail of inflammatory mediators called the Senescence-Associated Secretory Phenotype (SASP), including IL-6, IL-8, TNF-α, MMP-3, and MMP-9. In youth, the immune system (particularly NK cells) efficiently clears senescent cells. With aging, both senescent cell accumulation and clearance failure increase, resulting in a growing reservoir of SASP-secreting cells throughout tissues. Senolytics — drugs that selectively eliminate senescent cells — represent one of the most actively investigated longevity interventions.

2. Gut Dysbiosis and Leaky Gut — LPS Translocation

The gut microbiome undergoes significant compositional shifts with aging: reduced diversity, decreased short-chain fatty acid (SCFA) producers like Faecalibacterium prausnitzii, and increased gram-negative bacteria. When the intestinal epithelial barrier loses integrity — a condition called increased intestinal permeability or "leaky gut" — lipopolysaccharide (LPS), the endotoxin found in the outer membrane of gram-negative bacteria, translocates into the bloodstream. Circulating LPS activates Toll-like receptor 4 (TLR4) on immune cells and endothelial cells, triggering low-level but persistent inflammatory signaling. This mechanism — gut-derived "metabolic endotoxemia" — was characterized by Patrice Cani's group (2007) and is now recognized as a primary driver of chronic systemic inflammation in aging and metabolic disease. Sonnenburg's 2021 fermented food trial in Cell demonstrated that high-fermented food diets significantly increase microbiome diversity and measurably reduce inflammatory cytokines including IL-6, IL-12, and IL-17 in humans.

3. Mitochondrial Dysfunction and mtDNA Release

Mitochondrial function declines with age: electron transport chain efficiency decreases, reactive oxygen species (ROS) production increases, and mitochondrial membrane potential drops. Damaged mitochondria release mitochondrial DNA (mtDNA) into the cytoplasm and extracellular space. mtDNA — which shares structural features with bacterial DNA due to mitochondria's evolutionary origin as endosymbionts — activates cytosolic DNA sensors including cGAS-STING, triggering type I interferon and NF-κB inflammatory responses. This creates a feed-forward loop: mitochondrial dysfunction generates inflammatory signals that further damage mitochondria.

4. Chronic Viral Reactivation (CMV/EBV)

Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infect the majority of the global population during childhood and establish lifelong latency. In aging, immune decline allows for periodic reactivation, requiring continued immune surveillance. Chronic CMV reactivation is associated with accelerated immunosenescence — the age-related decline of adaptive immune function — and drives the chronic inflammatory tone seen in older adults. CMV-seropositive elderly individuals show significantly higher IL-6 and TNF-α levels than seronegative peers. The "immune inflation" driven by chronic CMV is considered a significant contributor to inflammaging that is difficult to modify directly.

5. Adipose Tissue Inflammation

Visceral adipose tissue is not metabolically inert. Fat cells (adipocytes) and their resident immune cells (adipose tissue macrophages, or ATMs) secrete a range of inflammatory adipokines including IL-6, TNF-α, MCP-1, and leptin. Visceral fat accumulation with aging — particularly as muscle mass declines — creates a progressively larger inflammatory source. Adipose tissue inflammation is self-amplifying: inflammatory cytokines promote insulin resistance, which promotes further fat storage, which increases cytokine output. Waist circumference and visceral fat area (measured by DEXA or CT) are among the strongest anthropometric predictors of systemic inflammatory markers in aging cohorts.

The Diseases Driven by Inflammaging

• Cardiovascular disease: Chronic low-grade inflammation drives endothelial dysfunction, promotes LDL oxidation and plaque formation, and destabilizes existing atherosclerotic plaques. IL-6 and CRP are independent cardiovascular risk factors (Ridker 2003). The CANTOS trial proved that targeting IL-1β with an antibody reduced major cardiovascular events by 15% in humans with prior MI and elevated CRP, independent of lipid-lowering.
• Alzheimer's disease and neurodegeneration: Neuroinflammation — mediated by activated microglia, IL-1β, TNF-α, and complement — is now recognized as a central pathological feature of Alzheimer's, not merely a downstream consequence of amyloid accumulation. Chronically elevated systemic IL-6 crosses the blood-brain barrier and activates central inflammatory cascades. Midlife elevated CRP predicts dementia onset decades later.
• Type 2 diabetes: TNF-α and IL-6 directly interfere with insulin receptor substrate signaling, reducing insulin sensitivity in skeletal muscle and adipose tissue. Inflammaging-driven insulin resistance predates clinical diabetes by decades and may be the primary mechanism linking visceral adiposity, aging, and metabolic disease.
• Cancer: NF-κB, the master transcriptional regulator of inflammation, also controls genes governing cell proliferation, survival, and invasion. Chronic NF-κB activation creates a tumor-permissive tissue environment. Elevated CRP is prospectively associated with increased incidence of multiple cancers including colorectal, lung, and endometrial cancer.
• Sarcopenia: TNF-α and IL-6 activate the ubiquitin-proteasome degradation pathway in skeletal muscle, accelerating muscle protein catabolism. Elevated IL-6 is one of the strongest independent predictors of muscle mass loss and physical function decline in aging (InCHIANTI cohort). Sarcopenia in turn reduces the anti-inflammatory buffering capacity of skeletal muscle, completing a vicious cycle.
• Depression and cognitive decline: The "cytokine hypothesis of depression" posits that elevated IL-6, TNF-α, and IL-1β alter tryptophan metabolism (reducing serotonin precursor availability), disrupt the hypothalamic-pituitary-adrenal axis, and impair neuroplasticity. Elevated inflammatory markers predict depression onset and treatment resistance.

Inflammaging Biomarkers: Reference Ranges and Longevity Targets

Dietary Interventions: What the Evidence Shows

Mediterranean Diet

The Mediterranean dietary pattern — abundant in extra-virgin olive oil, vegetables, legumes, fish, and polyphenol-rich foods, with minimal red meat and refined carbohydrates — has the strongest and most consistent body of evidence among dietary patterns for reducing inflammatory biomarkers. A 2019 meta-analysis of 17 randomized controlled trials (Schwingshackl et al.) found that adherence to the Mediterranean diet reduced circulating IL-6 by approximately 24% and CRP by 17–26% compared to control diets. The PREDIMED trial, involving 7,447 participants at high cardiovascular risk, demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events by 30% compared to a low-fat control diet. The anti-inflammatory effects are mediated by multiple mechanisms: oleocanthal in extra-virgin olive oil inhibits COX-1 and COX-2 (the same enzymes targeted by ibuprofen), polyphenols inhibit NF-κB, and omega-3 fatty acids compete with arachidonic acid for inflammatory enzyme substrates.

Omega-3 Fatty Acids (EPA + DHA)

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from marine sources reduce the synthesis of pro-inflammatory eicosanoids by competing with arachidonic acid (AA) for cyclooxygenase and lipoxygenase enzymes. Beyond substrate competition, EPA and DHA are precursors to specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins — that actively resolve inflammation rather than merely suppressing it. Meta-analyses consistently show that supplementation with 2–4g/day EPA+DHA reduces TNF-α and IL-6 significantly. The STRENGTH and ASCEND trials generated nuance around fish oil's cardiovascular benefits, but the anti-inflammatory effects on biomarkers are consistently replicated. Omega-3 index (percentage of EPA+DHA in red blood cell membranes) above 8% is associated with reduced cardiovascular risk and lower inflammatory markers; most Western populations sit at 4–5%.

Polyphenols: Resveratrol, Quercetin, and Curcumin

These plant-derived compounds share a common anti-inflammatory mechanism: inhibition of NF-κB nuclear translocation, reducing transcription of IL-6, TNF-α, IL-1β, and COX-2. Evidence varies by compound:

• Curcumin (from turmeric) has been extensively studied in RCTs. A 2016 meta-analysis (Sahebkar) of 8 RCTs found that curcumin supplementation significantly reduced CRP, IL-6, and TNF-α. Bioavailability is the central challenge — standard curcumin is poorly absorbed, but formulations with piperine (black pepper extract, 20mg) increase bioavailability by up to 2,000%. Effective doses: 400–800mg curcumin + piperine daily. Nanoparticle and phospholipid complex formulations (Meriva, Theracurmin) also show improved bioavailability.
• Quercetin is a flavonoid found in capers, onions, apples, and berries. Beyond NF-κB inhibition, quercetin has demonstrated senolytic activity in combination with dasatinib (the D+Q senolytic protocol) in both animal studies and early human trials (Mayo Clinic, Kirkland et al. 2019). As an anti-inflammatory, doses of 500–1,000mg/day have reduced IL-6 and TNF-α in clinical trials. Quercetin is also a zinc ionophore — facilitating zinc entry into cells, which has antiviral and anti-inflammatory implications.
• Resveratrol (found in red wine grapes, Japanese knotweed) activates SIRT1, a NAD+-dependent deacetylase that inhibits NF-κB and suppresses SASP in senescent cells. Human bioavailability is highly variable, and pivotal trials (Novartis SRT2104) showed limited systemic efficacy at commonly used doses. Micronized resveratrol or combination with quercetin may improve effectiveness. Current evidence supports its role as an adjunctive anti-inflammatory but not as a stand-alone longevity intervention.

Lifestyle Interventions: Exercise, Sleep, and Caloric Restriction

Exercise: The Anti-Inflammatory Paradox

Vigorous exercise causes an acute spike in inflammatory cytokines — IL-6 rises dramatically within minutes of intense effort. This is not harmful; it is the signaling cascade that drives adaptation. The paradox is that chronically, regular exercisers have significantly lower baseline inflammatory markers than sedentary individuals. Exercise's anti-inflammatory mechanisms include: reduced visceral adiposity (the largest addressable inflammatory source), increased production of anti-inflammatory myokines (particularly IL-10 and IL-1ra, which counterbalance the acute IL-6 spike), reduced monocyte activation, and increased parasympathetic tone (which suppresses systemic inflammation via the cholinergic anti-inflammatory pathway). A 2017 meta-analysis (Hayashino et al.) found that aerobic exercise training reduced CRP by approximately 1.3 mg/L and IL-6 by approximately 0.4 pg/mL in individuals with baseline elevation. Resistance training additionally preserves muscle mass, reducing the inflammatory contribution of sarcopenia. The dose: 150+ minutes of moderate aerobic activity plus 2 resistance sessions per week is the minimum; more VO2max-focused training appears to confer additional anti-inflammatory benefit.

Sleep: One Night of Deprivation Changes Your Cytokine Profile

Sleep is the primary period of inflammatory resolution. Studies by Irwin et al. consistently show that a single night of sleep deprivation (sleeping 4 hours instead of 8) produces significant increases in IL-6 and TNF-α the following day — equivalent to an acute stressor. Chronic short sleep (under 6 hours/night) is associated with CRP levels roughly 25% higher than adequate sleepers in epidemiological studies. Sleep deprivation activates NF-κB in immune cells, suppresses anti-inflammatory cytokines, and increases cortisol (which, paradoxically, causes downstream immune upregulation rather than suppression when chronic). Sleep quality — not just duration — matters: fragmented sleep with poor slow-wave sleep has similar inflammatory consequences to short sleep. Optimizing sleep is among the highest-leverage, zero-cost anti-inflammatory interventions available.

Caloric Restriction and Time-Restricted Eating

Caloric restriction (CR) — without malnutrition — consistently reduces NF-κB activity, lowers IL-6 and TNF-α, and extends lifespan in every model organism where it has been tested. In humans, the CALERIE trial (2022) demonstrated that a 12% caloric restriction for 2 years significantly reduced thymic inflammatory output and produced favorable shifts in inflammatory biomarkers. The mechanisms include: reduced mTORC1 activity (which normally suppresses autophagy and promotes inflammation when chronically elevated), increased AMPK activation, reduced adipose tissue mass, and improved mitochondrial efficiency. Time-restricted eating (eating within an 8–12 hour window) recapitulates some CR benefits without requiring calorie counting and has shown measurable reductions in CRP and IL-6 in clinical studies.

Supplements with Anti-Inflammatory Longevity Evidence

Diet and lifestyle are the primary levers. Supplements with meaningful evidence in the context of inflammaging include:

• Omega-3 (EPA+DHA, 2–4g/day): Reduces TNF-α, IL-6, and shifts eicosanoid balance toward resolution. Choose a triglyceride-form fish oil with third-party purity testing (IFOS certified). Krill oil provides phospholipid-bound omega-3s with better tissue incorporation at lower doses. Algal oil is the evidence-backed plant-based alternative.
• Quercetin (500–1,000mg/day): NF-κB inhibitor, senolytic activity in combination protocols, zinc ionophore. Take with bromelain for potentially enhanced absorption and synergistic anti-inflammatory effect. Evidence from human RCTs supports CRP and IL-6 reduction.
• Curcumin + piperine (400–800mg curcumin + 20mg piperine): Well-replicated reduction in CRP, IL-6, TNF-α in RCTs. Fat-soluble — take with a meal containing fat. Standardized to 95% curcuminoids. Avoid very high doses (>4g/day) without medical supervision as GI side effects become more common.
• Resveratrol (150–500mg/day): SIRT1 activator, NF-κB suppressor. Human evidence mixed; best used as part of a comprehensive protocol rather than stand-alone. Micronized forms or trans-resveratrol preferred.
• Magnesium (200–400mg/day): Magnesium deficiency — prevalent in 45–50% of Western populations — is independently associated with elevated CRP and IL-6. Supplementation in deficient individuals reliably reduces inflammatory markers. Magnesium glycinate or malate for best tolerance.
• Vitamin D3 (maintain serum 25(OH)D 40–60 ng/mL): Vitamin D receptors are expressed on virtually every immune cell type; deficiency accelerates macrophage inflammatory activation. Meta-analyses show that vitamin D supplementation reduces CRP and IL-6 in deficient individuals.

The Leaky Gut — Inflammaging Connection

The gut is the largest interface between the body and the external environment, lined by a single layer of epithelial cells connected by tight junction proteins (claudins, occludins, ZO-1). When these junctions degrade — driven by aging, dysbiotic microbiomes, alcohol, NSAIDs, high-fat diets, and chronic stress — the barrier becomes permeable to bacterial endotoxins. LPS from gram-negative bacteria crosses into portal circulation, activates hepatic Kupffer cells, and triggers systemic low-grade endotoxemia.

Patrice Cani's group demonstrated in 2007 that high-fat diet-induced gut dysbiosis in mice produced 2–3× increases in circulating LPS with corresponding increases in IL-6 and TNF-α — a state they termed "metabolic endotoxemia." Subsequent human studies confirmed that postprandial LPS elevation correlates with inflammatory biomarkers in metabolic syndrome and aging populations. The Sonnenburg lab's 2021 fermented food RCT in Cell (Wastyk et al.) showed that increasing fermented food intake for 10 weeks produced statistically significant reductions in 19 inflammatory proteins including IL-6, IL-12p70, and IL-17A — an effect that was consistent, robust, and mediated through increased microbiome diversity.

Gut-targeted interventions for inflammaging include: fermented foods (targeting microbiome diversity), prebiotic fibers (feeding SCFA producers that maintain tight junction integrity), and probiotic supplementation with Lactobacillus and Bifidobacterium species shown to reduce intestinal permeability markers (zonulin, I-FABP).

References and Further Reading

• Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. Journals of Gerontology Series A. 2014;69(Suppl 1):S4–S9.
• Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine. 2000;342(12):836–843.
• Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). NEJM. 2008;359(21):2195–2207.
• Wastyk HC, et al. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021;184(16):4137–4153. [Sonnenburg fermented food trial]
• Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). NEJM. 2017;377(12):1119–1131.
• Ferrucci L, et al. Serum IL-6 level and the development of disability in older persons. Journal of the American Geriatrics Society. 2002;50(11):2045–2049. [InCHIANTI study]
• Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents? A meta-analysis of randomized controlled trials. Phytomedicine. 2014;21(4):564–571.